Managing hematologic toxicities in the oncology patient.
Myelosuppression associated with antineoplastic therapy may lead to neutropenia, anemia, or both, resulting in an increased risk for infection, fatigue, diminished quality of life, and reduced survival. Neutropenia can result in dose reductions and treatment delays. Hematopoietic growth factors have been used effectively as supportive therapy to reduce antineoplastic therapy-associated neutropenia and anemia. This article discusses management of neutropenia and anemia secondary to antineoplastic therapy, new medications, and nursing considerations.
Montoya
Libby
L
Leukemia Lymphoma Service, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. libby.montoya@stjude.org
D000740:Anemia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects; D016903:Drug Monitoring / Q000451:nursing; D005334:Fever / Q000139:chemically induced; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000451:nursing; D009503:Neutropenia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000379:methods*; D010348:Patient Care Team / Q000458:organization & administration; D010353:Patient Education as Topic; D017751:Safety Management
D000970:Antineoplastic Agents